EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Long-Term Follow-Up of Patients With Follicular Lymphoma Using Next Generation Sequencing to Detect Minimal Residual Disease

Ayushi Chauhan, Catherine Lai, Frank Kuhr, Heidi Simmons, Bruce D Cheson

Clinical Lymphoma Myeloma and Leukemia · 2024-09 · 24 (9) · 634-641

DOI: 10.1016/j.clml.2024.04.009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2024-09. Verfasst von Ayushi Chauhan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Medical College of Georgia, Augusta, GA. Electronic address: Ayushichauhan.27@gmail.com. Hauptthemen laut MEDLINE: Lymphoma, Follicular, Neoplasm, Residual, High-Throughput Nucleotide Sequencing. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Adaptive Biotechnologies Corp.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Follicular lymphoma (FL) is a highly treatable, indolent non-Hodgkin lymphoma. Although FL is considered incurable, a patient without progression of disease by 24 months after treatment is predicted to have a survival consistent with persons without lymphoma. Using a sensitive assessment of minimal residual disease (MRD), we tested the hypothesis that MRD monitoring can predict long term remissions. METHODS: Unselected patients who were in a clinical remission for at least 24 months after their last treatment were enrolled and monitored prospectively for MRD detectability using a sensitive next-generation sequencing assay (clonoSEQ, Adaptive Biotechnologies, Seattle, WA). RESULTS: Forty-seven consecutive patients were monitored. We evaluated the MRD thresholds 10-4, 10-5, and 10-6 for the ability to predict long-term remissions in this cohort and determined that undetectable disease at 10-6 was the best predictor with a specificity and negative predictive value (NPV) of 70% and 100%, respectively. While 3 patients exhibited clinical disease progression during the course of the study, none of the 31 patients with persistent MRD undetectability at 10-6 experienced relapse. CONCLUSIONS: A significant proportion (31/47; 66.0%) of FL patients in clinical remission after ≥24 months following last therapy were undetectable at 10-6 by a sensitive assay of MRD. The threshold of sensitivity was 100%, specificity 70%, with a PPV of 19%, but a NPV of 100%. Although longer follow-up is needed for confirmation, many of these patients may continue to have durable complete remissions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, FollicularNeoplasm, ResidualHigh-Throughput Nucleotide SequencingHumansMaleFemaleMiddle AgedFollow-Up StudiesAgedAdultAged, 80 and over

Stichwörter der Autor:innen

MRD

Autor:innen und Institutionen

  • Medical College of Georgia, Augusta, GA. Electronic address: Ayushichauhan.27@gmail.com.
  • Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA.
  • Adaptive Biotechnologies, Seattle, WA.
  • Center for Cancer and Blood Disorders, Bethesda, MD.

Förderung

  • Adaptive Biotechnologies Corp

Zitieren

APA

Chauhan, A., Lai, C., Kuhr, F., Simmons, H., & Cheson, B. D. (2024). Long-Term Follow-Up of Patients With Follicular Lymphoma Using Next Generation Sequencing to Detect Minimal Residual Disease. Clinical Lymphoma Myeloma and Leukemia, 24(9), 634-641. https://doi.org/10.1016/j.clml.2024.04.009

Vancouver

Chauhan A, Lai C, Kuhr F, Simmons H, Cheson BD. Long-Term Follow-Up of Patients With Follicular Lymphoma Using Next Generation Sequencing to Detect Minimal Residual Disease. Clinical Lymphoma Myeloma and Leukemia. 2024;24(9):634-641. doi:10.1016/j.clml.2024.04.009

BibTeX
@article{Chauhan2024,
  author = {Chauhan, Ayushi and Lai, Catherine and Kuhr, Frank and Simmons, Heidi and Cheson, Bruce D},
  title = {Long-Term Follow-Up of Patients With Follicular Lymphoma Using Next Generation Sequencing to Detect Minimal Residual Disease},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2024},
  volume = {24},
  number = {9},
  pages = {634--641},
  doi = {10.1016/j.clml.2024.04.009}
}
Kostenlos starten →